Testing a new medicine for Cold Agglutinin Disease
Part of Blood & lymphatic clinical trials.
This Phase 1 study checks whether an investigational medicine is safe and tolerable, and how the body processes it. For people with Cold Agglutinin Disease, it also looks at early blood markers of whether the disease responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18–65 if you’re in the healthy-subject groups (otherwise at least 18).
- You must be non-pregnant and not breastfeeding; you must agree to use contraception if you could become pregnant.
- You must meet the study body size limits (BMI 18–32 and weight >50 kg for the healthy groups).
- You must have had a meningococcal ACWY vaccine within the past 5 years (or at least 14 days before starting).
- If you have Cold Agglutinin Disease (CAD), you must have a confirmed diagnosis, and certain blood tests must fit the study ranges.
- You must be able to understand the study and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational medicine in healthy adults to see how safe it is and how the body processes it. It is a first-in-human trial, so it is looking for volunteers who are generally well and have normal immune function.
This trial tests a new medicine in healthy people to see how safe it is and how the body handles it. It may help pave the way for future treatments.
This trial tests a single dose of an investigational drug called AMG 691 in healthy Chinese and Japanese volunteers to see how it is processed by the body and how safe it is. This is an early-phase study, so it may help make future treatments safer for people of similar backgrounds.
This study tests a new investigational drug called ISH0613 in healthy volunteers to see if it is safe and how the body processes it. It is the first time this drug is given to humans.
This study tests a new medicine in healthy people to see if it is safe and how the body handles it. Participating could help understand side effects before testing in patients.
This study tests a new medicine called HS-20152 in healthy people to see if it is safe and how the body handles it. It is an early-phase trial, so it helps find the right dose and check for side effects.
Hear when a new First in Man Study to Evaluate Initial Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.